Enjoy, and see you soon… A fast-growing group of Americans is turning to what many call the “gray market” for obesity ...

Though much of the dust has settled around Novo Nordisk and Eli Lilly’s crusade against compounded GLP-1s, the recent ...

In the race to make the most tolerable obesity drug, there seems to be no clear winner—at least not according to analysts ...

Data Insights Coronary Artery Disease (CAD) (Ischemic Heart Disease) drugs in development, 2024. The Coronary Artery Disease (CAD) (Ischemic Heart Disease) drugs in development market research report ...